CSIMarket


Adaptimmune Therapeutics Plc  (NASDAQ: ADAP)
Other Ticker:  
 

Adaptimmune Therapeutics Plc

ADAP's Fundamental analysis








Looking into Adaptimmune Therapeutics Plc growth rates, revenue grew by 354.13 % in III. Quarter 2024 from the same quarter a year ago. Ranking at No. 1674

Biotechnology & Pharmaceuticals industry recorded growth of revenues by 13.29 %

Adaptimmune Therapeutics Plc net loss decreased from $-46 millions, to $-18 millions in III. Quarter 2024,

More on ADAP's Growth


Adaptimmune Therapeutics Plc
realized a net loss in trailing twelve months.

Company is currently trading with Price to Cash flow multiple of 35 in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months.
Company
-
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 5.08.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.46.


More on ADAP's Valuation
 
 Total Debt (Millions $) 50
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 737,618
 Net Income/Employee (TTM) $ -
 Receivable Turnover (TTM) 30.17
 Tangible Book Value (Per Share $) 0.05

Adaptimmune Therapeutics Plc
realized net loss in trailing twelve months.

Company is currently trading with Price to Cash flow multiple of 35 in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months.
Company
-
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 5.08.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.46.

Adaptimmune Therapeutics Plc Price to Book Ratio is at 11.53 higher than Industry Avg. of -0, and higher than S&P 500 Avg. of 0.02

More on ADAP's Valuation

  Market Capitalization (Millions $) 922
  Shares Outstanding (Millions) 1,535
  Employees 246
  Revenues (TTM) (Millions $) 181
  Net Income (TTM) (Millions $) -45
  Cash Flow (TTM) (Millions $) 26
  Capital Exp. (TTM) (Millions $) -2
  Total Debt (Millions $) 50
  Dividend TTM ($) 0 $
  Dividend Yield TTM (%) -
  Revenue/Employee (TTM) $ 737,618
  Net Income/Employee(TTM) $ -
  Receivable Turnover Ratio (TTM) 30.17
  Tangible Book Value (Per Share $) 0.05

  Market Capitalization (Millions $) 922
  Shares Outstanding (Millions) 1,535
  Employees 246
  Revenues (TTM) (Millions $) 181
  Net Income (TTM) (Millions $) -45
  Cash Flow (TTM) (Millions $) 26
  Capital Exp. (TTM) (Millions $) -2





  Ratio
   Capital Ratio (MRQ) 3.85
  Total Debt to Equity (MRQ) 0.62
  Tangible Leverage Ratio (MRQ) 3.14
  Asset Turnover Ratio (TTM) 0.61
  Inventory Turnover Ratio (TTM) -





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com